Browse studies

Find your next paid study

33 recruiting studies matching your filters

Natural History Study of Men at High Genetic Risk for Prostate Cancer

Background: Research studies have shown that genetic changes and family history may increase a man s risk for prostate cancer. Researchers want to follow the …

Prostatic Neoplasms

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT03805919

Phase 3

MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)

The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalut…

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT06136650

Phase 1

MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger…

Prostatic Neoplasms, Castration-Resistant

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT06353386

Phase 3

A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinat…

Prostate CancerProstatic Neoplasms

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT06925737

Collection of Blood From Patients With Prostate Cancer

Background: * It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but ge…

Cancer Of ProstateProstate CancerProstatic Neoplasms+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT00923221

Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies

Background: \- Radiation is a common treatment for prostate cancer. It helps damage tumor cells and causes them to die. Radiation can be effective, but some t…

Prostatic NeoplasmsProstate Cancer

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT01834001

Phase 1

A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer

The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 an…

Prostatic Neoplasms

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT06095089

Observational

Cancer Oriented Understanding and Navigation Via Supportive and Educational Language Models (COUNSEL)

A randomized, open-label behavioral study designed to evaluate the feasibility, acceptability, and early impact of a large language model (LLM)-based artificia…

Prostate CancerProstatic NeoplasmsPatient Education as Topic

Estimated

~$10 – $5,625

University of California, San FranciscoNCT07836933

Phase 1

A Phase 1 Trial of JNJ-98768111, an Antibody Drug Conjugate (ADC) Targeting Human Kallikrein-2 (KLK2) for Advanced Prostate Cancer

The purpose of Part 1 of this study is to find out how safe JNJ-98768111 is and the most suitable dose (recommended phase 2 dose \[RP2D\]) regimen(s) of JNJ-98…

Prostatic Neoplasms

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT07746713

Phase 1

A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer

The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose findin…

Prostatic Neoplasms

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT07319871

Phase 3

A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of …

Prostatic Neoplasms, Castration-Resistant

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT07225946

Phase 1

A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-95298177, an Antibody Drug Conjugate Targeting Prostate Specific Membrane Antigen, for Prostate Cancer

The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose conf…

Prostatic Neoplasms

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT07082920